SNA02-48

BIOLOGICAL2 trials

Sponsors

Sinovac Life Sciences Co., Ltd.

Conditions

Tetanus

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants

CompletedNCT06939777

Sinovac Life Sciences Co., Ltd.Tetanus

Start: 2025-04-28End: 2026-03-30Updated: 2026-06-03

Phase 3

A Phase Ⅲ Clinical Study of SNA02-48 Injection

Not yet recruitingNCT07633119

Sinovac Life Sciences Co., Ltd.Tetanus

Start: 2026-06-28End: 2027-05-31Target: 600Updated: 2026-06-08